B. Braun Hemodialysis Blood Tubing Set Recall - Air Bubble Risk

Health Canada issued a Type II recall for B. Braun Hemodialysis Blood Tubing Sets (models B3-4630M4705 and B3-3632M3705) due to potential accumulation of small air bubbles in the arterial line caused by adherence of blood gases to tubing under negative pressure. All lots are affected. Healthcare providers should immediately identify and remove affected products from use and contact the manufacturer for return or replacement instructions.

DermaHealer UVB Light Therapy Lamps Recalled for Lacking Canadian Medical Device Licence

Health Canada issued a Type II recall for DermaHealer UVB Light Therapy Lamps (Handheld and Compact models) distributed in Canada without required Canadian Medical Device Licence. The products were sold to customers across Canada by manufacturer DermaHealer USA/UAB FavouritePlus of Tualatin, Oregon. No specific lot or model numbers are available; customers must contact the manufacturer for identification.

Jamieson Laboratories Products Recall - Defective Tamper-Evident Seals

Health Canada issued a Type III recall for Jamieson Laboratories three natural health product capsule lines due to potentially defective tamper-evident seals. Affected products include Joint pain relief capsules (NPN 80140241, lot 70794), Magnesium bisglycinate Capsules (NPN 80131651, 12 lots), and Maca capsules (NPN 80134082, 3 lots). The recall depth extends to wholesalers and retailers. No compliance deadline or penalties are specified.

eSACEPO Digital Patent Process Meeting Highlights

The European Patent Office's 11th eSACEPO Working Party meeting on March 24, 2026 discussed progress toward a fully digitalized, paperless patent granting process (PGP) by 2027. Key updates include MyEPO platform enhancements, end-to-end DOCX filing launching April 1, 2026, and AI integration with human oversight. Electronic filing will become the default standard with paper filings limited to exceptional cases.

Updated Patent Examination Guidelines Enter Force

The European Patent Office has updated the EPC Guidelines, PCT-EPO Guidelines, and Unitary Patent Guidelines, effective 1 April 2026. The European Patent Guide and Euro-PCT Guide are being discontinued with content integrated into the Guidelines; they remain available until 31 May 2026. A public consultation on the 2026 editions is open until 3 April 2026.

UK FCA Wholesale Markets Regulatory Priorities

The UK FCA published regulatory priorities reports for wholesale markets and wholesale buy side sectors, replacing previous portfolio letters. The wholesale markets priorities focus on operational resilience, market competition and innovation, new technology adoption, financial crime prevention, and conflicts management. The wholesale buy side priorities emphasize growth and innovation, consumer duty implementation, private market investing standards, and market integrity.

EU State Aid Rules for Banks in Difficulty - Call for Evidence on Revision

The European Commission has launched a call for evidence on revising EU state aid rules for banks in difficulty. The initiative proposes to consolidate six existing crisis-era communications into a single, clearer framework aligned with the EU Crisis Management and Deposit Insurance (CMDI) framework. Feedback deadline is 14 April 2026, with final adoption planned for Q2 2027.

Historic AML Penalty on Broker-Dealer for BSA Violations

FinCEN assessed a historic $80 million civil money penalty against Canaccord Genuity LLC for willful violations of the Bank Secrecy Act—the largest-ever penalty imposed by FinCEN against a broker-dealer. The enforcement action addresses failures spanning March 2018 through June 2024 related to AML program deficiencies, suspicious activity reporting, and customer/correspondent due diligence. FinCEN agreed to suspend $5 million of the penalty while crediting $20 million payments to the SEC and $20 million to FINRA, resulting in a net $35 million payable to Treasury.

UK FCA Bans Turkish Executive for Compliance Failures and Forgery

The UK FCA banned Kasim Garipoglu, a Turkish national and former CEO/beneficial owner of a UK-regulated firm, from working in UK financial services. The FCA found he lacked honesty and integrity, fostered a culture of non-compliance, instructed staff to circumvent AML controls, and created forged documents. The action underscores FCA emphasis on individual accountability and tone-from-top compliance culture.

DOL Proposes Rule on ERISA Fiduciary Duties for 401(k) Investments

The Department of Labor released a proposed rule titled 'Fiduciary Duties in Selecting Designated Investment Alternatives' to clarify how ERISA fiduciaries satisfy their duty of prudence when selecting and monitoring 401(k) and 403(b) investment options. The proposed rule establishes a six-factor safe harbor (performance, fees, liquidity, valuation, benchmarking, and complexity) for documented fiduciary decision-making.